- Home
- VSCO vs VCYT Comparison
VSCO vs VCYT Comparison
Compare VSCO & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSCO | VCYT |
|---|---|---|
| Founded | 1977 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.9B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | VSCO | VCYT |
|---|---|---|
| Price | $42.01 | $46.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $30.83 | ★ $44.44 |
| AVG Volume (30 Days) | ★ 2.2M | 1.2M |
| Earning Date | 12-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.76 | N/A |
| EPS | ★ 1.86 | 0.38 |
| Revenue | ★ $6,265,000,000.00 | $495,141,000.00 |
| Revenue This Year | $4.61 | $16.02 |
| Revenue Next Year | $2.90 | $10.74 |
| P/E Ratio | ★ $22.62 | $122.79 |
| Revenue Growth | 2.29 | ★ 16.41 |
| 52 Week Low | $13.76 | $22.61 |
| 52 Week High | $48.73 | $50.71 |
Technical Indicators
Market Signals| Indicator | VSCO | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 67.96 | 64.28 |
| Support Level | $33.70 | $37.98 |
| Resistance Level | $44.38 | $50.71 |
| Average True Range (ATR) | 2.14 | 2.07 |
| MACD | 0.59 | 0.37 |
| Stochastic Oscillator | 77.02 | 67.32 |
Price Performance
Historical ComparisonAbout VSCO Victorias Secret & Co.
Victoria's Secret & Co is a retailer of women's intimate and other apparel and beauty products marketed under the Victoria's Secret, PINK, and Adore Me brand names. It also includes the merchandise sourcing and production function serving the Company and its international partners. The Company operates as a single segment designed to serve customers seamlessly through stores and online channels.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.